

Kimberley Joanne Hatfield

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8765574/publications.pdf>

Version: 2024-02-01

24
papers

906
citations

471509

17
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1184
citing authors

#	ARTICLE	IF	CITATIONS
1	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2907.	4.1	158
2	The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2007, 136, 814-828.	2.5	115
3	Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. <i>International Journal of Cancer</i> , 2006, 119, 2313-2321.	5.1	75
4	Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. <i>British Journal of Haematology</i> , 2009, 144, 53-68.	2.5	61
5	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. <i>Stem Cell Research</i> , 2015, 15, 530-541.	0.7	51
6	Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. <i>Cytotherapy</i> , 2016, 18, 172-185.	0.7	49
7	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 20.	17.1	46
8	Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. <i>Oncotarget</i> , 2013, 4, 830-843.	1.8	43
9	Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. <i>Hematology</i> , 2011, 16, 351-356.	1.5	38
10	Hypoxia increases HIF-1 α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. <i>European Cytokine Network</i> , 2010, 21, 154-64.	2.0	36
11	The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. <i>Metabolomics</i> , 2016, 12, 12.	3.0	34
12	Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity. <i>Cells</i> , 2020, 9, 1155.	4.1	25
13	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. <i>Cancers</i> , 2018, 10, 332.	3.7	24
14	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 382.	4.1	20
15	Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors. <i>Metabolomics</i> , 2017, 13, 2.	3.0	19
16	Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. <i>International Journal of Oncology</i> , 2007, 31, 1529-38.	3.3	19
17	Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. <i>Cells</i> , 2019, 8, 1229.	4.1	18
18	Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. <i>International Journal of Oncology</i> , 2007, , .	3.3	17

#	ARTICLE	IF	CITATIONS
19	Targeting of cell metabolism in human acute myeloid leukemia â€” more than targeting of isocitrate dehydrogenase mutations and <sc>PI</sc>3K/<sc>AKT</sc>/<sc>mTOR</sc> signaling?. European Journal of Haematology, 2016, 96, 211-221.	2.2	16
20	Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation. Journal of Transplantation, 2014, 2014, 1-9.	0.5	15
21	Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome. Disease Markers, 2015, 2015, 1-13.	1.3	15
22	MicroRNA serum profiles and chronic graft-versus-host disease. Blood Advances, 2022, 6, 5295-5306.	5.2	6
23	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. Cytotherapy, 2018, 20, 740-754.	0.7	5
24	Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules, 2022, 12, 492.	4.0	1